Abstract: An extended release pharmaceutical composition comprising levetiracetam. A coated extended release pharmaceutical composition comprising levetiracetam wherein the core is coated with a rate controlling composition.

Abstract: For improving the accuracy of a speech recognition system, for the specific task of speech-to-text (dictation style speech) translation, a constrained dictation methodology using speak-and-spell mode is disclosed. The invention is perfectly suited for modern day “text-messaging” applications wherein the number of words being dictated is very small (limited by the 140-160 characters message length constraint). Additionally, the invention adds a control on the way users interact with machines, thereby making the speech recognition task easier and improving system accuracy.

Abstract: The invention relates to process for the treatment of a hydrophobic surface by a liquid film comprising an aqueous phase comprising the coating of said surface by the liquid whose aqueous phase comprises an effective amount of surface properties modifying agent and an active agent.

Abstract: An article includes (a) a glass substrate having a modified surface that comprises a glass surface and a layer of nanoscale inorganic oxide particles disposed in contact with and bound to at least a portion of the glass surface, and (b) a polymer layer disposed in contact with and bound to the modified glass surface. A method for improving the hydrolytic stability of an interface of a glass surface and a polymer surface, includes the step of, prior to forming the interface of the glass surface and the polymer surface, treating at least a portion of the glass surface with nanoscale inorganic oxide particles to modify the glass surface by depositing a quantity of such particles on the portion of the surface.

Abstract: A surface modified substrate includes a substrate having a surface and a layer of nanoscale inorganic oxide particles disposed on at least a portion of the surface.

Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).

Abstract: The present invention relates to extended release pharmaceutical compositions of Levetiracetam and processes for preparing the same. The extended release tablet of Levetiracetam is with a core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patient's blood plasma. The composition also exhibits no food effect.

Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: L is selected from the group consisting of: ?pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).

Abstract: A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.

Abstract: A compound having the general structure shown in Formula (I): or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

Abstract: A system comprising a first double data rate (DDR) memory device, a second DDR memory device coupled to the first DDR memory device, the second DDR memory device not using a delay locked loop (DLL) device to synchronize clock signals. The system further comprises a logic coupled to the first and second DDR memory devices. The logic is adapted to receive data from the first and second DDR memory devices by way of a single conductive pathway.

Abstract: A computer-based method of routing a message to a system includes receiving a message, and processing the message using large-vocabulary continuous speech recognition to generate a string of text corresponding to the message. The method includes generating a confidence estimate of the string of text corresponding to the message and comparing the confidence estimate to a predetermined threshold. If the confidence estimate satisfies the predetermined threshold, the string of text is forwarded to the system. If the confidence estimate does not satisfy the predetermined threshold, the information relating to the message is forwarded to a transcriptionist. The message may include one or more utterances. Each utterance in the message may be separately or jointly processed. In this way, a confidence estimate may be generated and evaluated for each utterance or for the whole message. Information relating to each utterance may be separately or jointly forwarded based on the results of the generation and evaluation.

Abstract: For improving the accuracy of a speech recognition system, for the specific task of speech-to-text (dictation style speech) translation, a constrained dictation methodology using speak-and-spell mode is disclosed. The invention is perfectly suited for modern day “text-messaging” applications wherein the number of words being dictated is very small (limited by the 140-160 characters message length constraint). Additionally, the invention adds a control on the way users interact with machines, thereby making the speech recognition task easier and improving system accuracy.

Abstract: For improving the accuracy of a speech recognition system, for the specific task of character recognition, the character that is to be recognized or interpreted, is spoken in accordance with this invention, using simple coding-schemes that result in acoustic renderings that are well separated in the acoustic space. Furthermore, to relax the constraint on users for memorizing multiple words associated with multiple characters, in one embodiment, the coding-schemes are defined based on a combination of the given character and its neighboring/succeeding character(s).

Abstract: A computer-based method of routing a message to a system includes receiving a message, and processing the message using large-vocabulary continuous speech recognition to generate a string of text corresponding to the message. The method includes generating a confidence estimate of the string of text corresponding to the message and comparing the confidence estimate to a predetermined threshold. If the confidence estimate satisfies the predetermined threshold, the string of text is forwarded to the system. If the confidence estimate does not satisfy the predetermined threshold, the information relating to the message is forwarded to a transcriptionist. The message may include one or more utterances. Each utterance in the message may be separately or jointly processed. In this way, a confidence estimate may be generated and evaluated for each utterance or for the whole message. Information relating to each utterance may be separately or jointly forwarded based on the results of the generation and evaluation.